Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
$338,439Michael J Overman · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$338,378Kian H Lim · Washington University · R37 · FY2019 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$338,378David G Denardo · Washington University · R01 · FY2019 · CA
Role of RON kinase in anti-tumor immune responses
$338,378Alana L Welm · University Of Utah · R01 · FY2019 · CA
Project 2: Determinants of Response and Resistance to DNA-Damaging Radiation Plus Immunotherapy Combinations in Triple Negative Breast Cancer
$338,306Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · P50 · FY2024 · CA
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy
$338,182David G Denardo · Washington University · P50 · FY2017 · CA
Project 3
$338,116John L. Cleveland · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2025 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity
$338,099David C Linehan · University Of Rochester · R01 · FY2022 · CA
Molecular Analysis of Chromosomal Fragile Sites
$338,085University Of Chicago · R01 · FY2002 · CA
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy
$338,071Szu-Wen Wang · University Of California-Irvine · R01 · FY2020 · EB
Project 3
$338,052John L. Cleveland · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2023 · CA
Integration of stromal targeting agents with immune checkpoint therapy
$338,040Lei Zheng · Johns Hopkins University · P01 · FY2022 · CA
How do cyclins drive the cell cycle?
$338,000Frederick R. Cross · Rockefeller University · R01 · FY2007 · GM
How do cyclins drive the cell cycle?
$338,000Frederick R. Cross · Rockefeller University · R01 · FY2009 · GM
How do cyclins drive the cell cycle?
$338,000Frederick R. Cross · Rockefeller University · R01 · FY2008 · GM
Melanoma Immunotherapy with GPR182 blockade
$337,922Yuwen Zhu · University Of Colorado Denver · R01 · FY2024 · CA
The CD93 pathway and melanoma therapy
$337,922Yuwen Zhu · University Of Colorado Denver · R01 · FY2024 · CA
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
$337,922Kian H Lim · Washington University · R37 · FY2024 · CA
MDC1: central regulator of estrogen receptor function and therapy response in lobular carcinoma
$337,922Matthew J Sikora · University Of Colorado Denver · R01 · FY2024 · CA
The GPR171 pathway in cancer immunotherapy
$337,922Yuwen Zhu · University Of Colorado Denver · R01 · FY2024 · CA
Regulation of DNA replication kinetics by BRCA2 after DNA damage
$337,877Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Regulation of DNA replication kinetics by BRCA2 after DNA damage
$337,877Bing Xia · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA
Structural studies of molecular cancer targets and drug development
$337,814David S Waugh · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
The MRAD9 Radioresistance Gene
$337,733Howard B Lieberman · Columbia University Health Sciences · R01 · FY2010 · GM
CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
$337,690Sloan-Kettering Institute For Cancer Res · R01 · FY2001 · CA